Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 18 June 2009, Vol. 113, No. 25, pp. 6382-6385.
Prepublished online as a Blood First Edition Paper on February 20, 2009; DOI 10.1182/blood-2009-01-198564.

This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2009-01-198564v1
113/25/6382    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swann, J. B.
Right arrow Articles by Smyth, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swann, J. B.
Right arrow Articles by Smyth, M. J.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted January 9, 2009
Accepted February 8, 2009

Type I NKT cells suppress tumors in mice caused by p53 loss

Jeremy B. Swann, Adam P. Uldrich, Serani van Dommelen, Janelle Sharkey, William K. Murray, Dale I. Godfrey, and Mark J. Smyth*

Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Department of Microbiology & Immunology, University of Melbourne, Parkville, Victoria, Australia
Department of pathology, University of Melbourne, Parkville, Victoria, Australia

* Corresponding author; email: mark.smyth{at}petermac.org.

CD1d-restricted T cells are considered to play a host protective effect in tumor immunity, yet the evidence for a role of NKT cells in tumor immune surveillance has been weak and data from several tumor models has suggested that some (type-2) CD1d-restricted T cells may also suppress some types of anti-tumor immune response. To substantiate an important role for CD1d-restricted T cells in host response to cancer, we have evaluated tumor development in p53+/- mice lacking either type-I NKT cells (TCR J{alpha}18-/-) or all CD1d-restricted T cells (CD1d-/-). Our findings support a key role for type-I NKT cells in suppressing the onset of sarcomas and hematopoietic cancers caused by p53 loss but do not suggest that other CD1d-restricted T cells are critical in regulating the same tumor development.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

NKT cells in p53 deficiency
Madhav V. Dhodapkar and Natalia Neparidze
Blood 2009 113: 6268-6269. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BloodHome page
M. V. Dhodapkar and N. Neparidze
NKT cells in p53 deficiency
Blood, June 18, 2009; 113(25): 6268 - 6269.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020